Novel drug could be world’s first treatment for a pediatric brain cancer

Written by Mike Gregg, Future Science Group

A novel drug that targets a genetic weakness in an untreatable childhood brain cancer has shown promise in preclinical trials and could become the first treatment developed to target diffuse intrinsic pontine glioma (DIPG). The drug has also shown promise in treating patients that have stone man syndrome, a condition in which muscles and ligaments turn to bone. Scientists at The Institute of Cancer Research (London, UK) have led an international team to develop a drug, which could treat DIPG. The development of this drug has come at a critical time as no new drugs have been licensed to treat...

To view this content, please register now for access

It's completely free